September 8, 2015
Financing will advance Sanifit's lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and throughphase II/III for calciphylaxis.Palma de Mallorca, Spain, September 8, 2015 - Laboratoris Sanifit S.L., a clinical-stagebiopharmaceutical company, today announces that it has raised ?36.6M ($41.3M) in a SeriesC financing round. The company is focused on the...


Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020
Ancient DNA throws a ‘scientific hand grenade’ into the discussion about the arrival of humans in North America
23. July 2020
Danish researchers map key disease mechanism – and describe a completely new protein
20. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge